Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Advanced Nonhematologic Malignancies 2Waldenstrom Macroglobulinemia 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Somatostatinoma 1Recurrent Malignant Solid Neoplasm 1Recurrent Lung Squamous Cell Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-hematologic Malignancy 1Neoplasms 1Multiple Myeloma 1Metastatic Castration-Resistant Prostate Cancer 1Lung Neoplasms 1Hematologic Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Burkitt Lymphoma 1Advanced Solid Tumors 1Advanced Solid Tumor 1Advanced Solid Malignancies 1Adenoma, Islet Cell 1

Interventions

pembrolizumab 6Nivolumab 6Ipilimumab 4Radiotherapy 3talimogene laherparepvec 2budigalimab 2avelumab 2atezolizumab 2Everolimus 2Cyclophosphamide 2zimberelimab 1venetoclax 1vatalanib 1tremelimumab 1temsirolimus 1sapanisertib 1rovalpituzumab tesirine 1poly ICLC 1oblimersen 1lorvotuzumab mertansine 1lanreotide 1glucopyranosyl lipid-A 1fludarabine 1durvalumab 1domatinostat 1cixutumumab 1cemiplimab 1aldesleukin 1Vinorelbine 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Merkel Cell × sapanisertib × Clear all
NCT02514824 2020-12-29

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

Dana-Farber Cancer Institute

Phase 1/2 Completed
9 enrolled 10 charts
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡